New Tri-Specific antibody takes on Hard-to-Treat myeloma
NCT ID NCT06375044
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called SIM0500 in 130 adults with multiple myeloma that has returned or stopped responding to treatment. SIM0500 is a tri-specific antibody designed to help the immune system attack cancer cells. The study will first find the safest dose, then test that dose more closely, while monitoring side effects and any tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SIM0500 (a tri-specific antibody targeting GPRC5D, BCMA, and CD3 proteins)
What this could lead to
If successful, this could lead to a new treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 130 participants, so safety and effectiveness are not yet proven. Side effects from the immune system activation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Beijing Chaoyang Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact
-
Dana Farber Cancer institution
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
Contact
-
Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute
RECRUITINGNew York, New York, 10029, United States
Contact
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact
-
Mayo Clinic Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact Phone: •••-•••-••••
Contact
-
Mayo Clinic Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-••••
Contact
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
-
The First Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHanzhou, Zhejiang, 310000, China
Contact